Institutional & Family Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Institutional & Family Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8	Closed	-$1K	–	832
2022 Q1	$1K	Hold	8	–	–	﹤0.01%	757
2021 Q4	$1K	Hold	8	–	–	﹤0.01%	787
2021 Q3	$1K	Sell	8 -5	-38%	-$624	﹤0.01%	901
2021 Q2	$1K	Hold	13	–	–	﹤0.01%	939
2021 Q1	$1K	Sell	13 -8	-38%	-$647	﹤0.01%	924
2020 Q4	$2K	Sell	21 -1	-5%	-$85	﹤0.01%	815
2020 Q3	$1K	Hold	22	–	–	﹤0.01%	825
2020 Q2	$2K	Sell	22 -7	-24%	-$373	﹤0.01%	743
2020 Q1	$1K	Hold	29	–	–	﹤0.01%	805
2019 Q4	$2K	Sell	29 -13	-31%	-$644	﹤0.01%	787
2019 Q3	$2K	Buy	42 +1	+2%	+$42	﹤0.01%	758
2019 Q2	$2K	Hold	41	–	–	﹤0.01%	774
2019 Q1	$2K	Hold	41	–	–	﹤0.01%	764
2018 Q4	$2K	Hold	41	–	–	﹤0.01%	738
2018 Q3	$2K	Sell	41 -7	-15%	-$257	﹤0.01%	783
2018 Q2	$2K	Hold	48	–	–	﹤0.01%	770
2018 Q1	$1K	Buy	+48	New	+$1.44K	﹤0.01%	843

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Institutional & Family Asset Management's BHVN Position: Q2 2022 in Review

Institutional & Family Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 8 shares — an estimated $1K sold.

Institutional & Family Asset Management first reported a position in BHVN in Q1 2018 and held it in 17 quarters. The position peaked at $2K in Q4 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Institutional & Family Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Institutional & Family Asset Management sold 8 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $1K.
Institutional & Family Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018 and held it in 17 quarters.
Institutional & Family Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $2K in Q4 2020.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Institutional & Family Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.